Ireland's Horizon Pharma Plc today said it would acquire U.S. drugmaker Hyperion Therapeutics Inc in an all-cash deal worth about $1.1 billion.
Horizon will pay $46 per share, representing a premium of 7.6 percent to Hyperion's Friday closing price. (Reuters)
For more visit: www.businessworld.ie